Navigation Links
Portrait(R) Plasma Receives Clearance from the FDA to Treat Acne Scars
Date:4/2/2008

WALTHAM, Mass., April 2, 2008 /PRNewswire/ -- Rhytec, Inc. the pioneer of plasma skin regeneration and sole provider of an aesthetic device which uses a novel thermal energy called plasma for reversing the signs of aging, today announced it has received U.S. Food and Drug Administration (FDA) clearance to market a new indication for treating acne scars. Portrait(R) Plasma is already cleared by the FDA for treating facial and non-facial areas for wrinkles, superficial skin lesions, actinic keratosis, seborrhoeic keratosis and viral papillomata.

An initial single site clinical study treating acne scars was conducted using the Portrait PSR3 plasma system. M. Potter, et al, evaluated 9 patients after one Portrait Plasma treatment and found acne scarring improved by 23% at six months and sustained for two years. Although this sample size was limited, an objective evaluation method was used as compared to the subjective methods (visual observation) used in most other studies. Silicone elastomer molds were made of the skin irregularities before and after treatment and compared by measuring the depth of the defects. A 35% decrease in acne scar depth was found in this elastomer evaluation (Potter et al. Annals of Plastic Surgery. Volume 58, Number 6, June 2007).

Rhytec then conducted a multi-center IRB clinical study at three sites evaluating Portrait Plasma treatment of areas of sunken, atrophic, post acne scars (G. Lask/P. Yamauchi, J.F. Tremblay & N. Uebelhoer). Twenty-nine patients completed the one treatment protocol with physicians reporting a mean improvement of 29% in acne scar appearance at 6 months. Patient self assessment was 35% average improvement and seventy-one percent (71%) of patients would recommend the procedure to a friend. These results were obtained after a single Portrait(R) Plasma treatment compared to the six treatments patients endure with the 1320 nm Nd:Yag and up to 5 treatments with fractional lasers.

Portrait Plasma is a one of its kind - novel, non-invasive, in-office technology clinically proven to treat unhealthy signs of aging often accelerated by sun exposure and acne scars. Plasma treats 100% of the skin; it stimulates a natural response producing healthier regeneration of the skin. Different from lasers which only target specific components of the skin, physicians and patients feel that with plasma's unique approach results are maximized. This is especially important when treating acne scars, all wrinkles, skin laxity and pre-cancerous lesions, such as actinic keratosis. Further, unlike other procedures on the market, like CO2, erbium, or fractionated lasers, Portrait Plasma offers less downtime and little to no risk of hypopigmentation, scarring or discoloration as seen in this clinical study.

About Portrait Plasma:

Portrait(R) PSR3 harnesses the power of plasma to deliver dramatic skincare results without the risk or down time associated with laser procedures. The hand-piece delivers nitrogen plasma energy that works both at and below the surface of the skin to modify its architecture and generate new collagen for up to two years. Portrait Plasma has been proven to treat fine lines and deep wrinkles, sun damage, pre-cancerous lesions, dyschromia and tighten skin. It also improves pore size, elasticity, and tone and texture of the face and body.

About Rhytec - The Makers of Portrait Plasma:

Rhytec develops innovative plasma technologies based on sound scientific and clinical research for the dermatological, plastic and cosmetic surgery markets. Plasma energy stimulates a true, natural skin regenerative process that is supported by over 30 completed and ongoing clinical trials. Founded in 2004, Rhytec works with leading dermatologists, plastic surgeons, and cosmetic physicians to develop new technologies that enhance the skin's appearance and function, improving the quality of life for patients seeking treatment. Rhytec, Inc. is privately held, based in Waltham, MA (US), and is a subsidiary of Rhytec, Ltd. in Berkshire (UK).


'/>"/>
SOURCE Rhytec, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Data From Antheras Plasma Trial to be Presented as Late Breaker at American College Of Cardiology Scientific Sessions
2. Toxoplasma infection increases risk of schizophrenia, study suggests
3. Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
4. Test gives insight into prognosis in patients with plasma cell malignancies, finds Mayo Clinic study
5. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
6. New Studies Find Plasma Disc Decompression Effective for Contained Disc Herniation
7. CryoCor Reports Going Concern Statement and Receives Notification From Nasdaq Relating to Minimum Stockholders Equity
8. Western Reserve Heart Care Receives ICANL Nuclear Medicine Accreditation
9. AIDS Activist Gregg Gonsalves Receives $100,000 Leadership Award
10. Emageon Receives Best in KLAS Cardiology PACS Award
11. London Luxury Receives Asthma & Allergy Friendly(TM) Certification for Several of Its Bedding Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... June 27, 2016 Jazz Pharmaceuticals plc (Nasdaq: ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as ... Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: CPXX ) ... Daylight Time). As previously announced on May ... definitive merger agreement under which Jazz Pharmaceuticals has commenced ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: